OREANDA-NEWS. December 10, 2015. Solid interim results:  First half results to 30th September demonstrate clear progress against the Board's objective of creating a business with at least a 100m valuation by 2020.

Proforma sales growth of 97%, driven by new customer contract wins and by pipeline progress from existing customers' medical device programmes. The potential for operations in China (via joint venture) and the development of a new production facility for a global device manufacturer are both in late stage discussions which would underpin longer term growth, if successfully executed.

The long term pipeline continues to build with strategic collaborations.